Parkin disease is usually autosomal recessive; however, two studies have shown that asymptomatic heterozygotes have nigrostriatal dysfunction and even manifest subtle extrapyramidal signs. The authors used 18 F-dopa PET to study 13 asymptomatic parkin heterozygotes and found a significant reduction of 18 F-dopa uptake in caudate, putamen, ventral, and dorsal midbrain compared with control subjects. Four had subtle extrapyramidal signs. Parkin heterozygosity is a risk factor for nigrostriatal dysfunction and in some may contribute to late-onset Parkinson disease.
Mutations in parkin, PARK2 (MIM 600116), cause early-onset parkinsonism. 1 Although the inheritance is autosomal recessive, there is a risk of subjects with a single mutation developing parkin or Parkinson disease (PD) 1 and cases of late-onset parkin disease with a single mutant allele. 1 The relatives of patients with parkin who carry a single mutant allele may have PET evidence of nigrostriatal abnormalities and may even manifest subtle extrapyramidal signs 2 as seen in autosomal recessive PARK6-linked early-onset parkinsonism. 3 PARK2 heterozygotes also may even have a susceptibility to psychiatric illness. 4 To date, functional imaging has been performed in asymptomatic parkin heterozygotes from just two families. 2, 4 We used 18 F-dopa PET to study 13 asymptomatic first-degree relatives with a single parkin mutation from 8 unrelated patients with familial or isolated parkin disease.
Subjects and methods. Subjects. We studied 13 asymptomatic parkin heterozygotes (Subjects 1 through 13; table 1) from 8 unrelated parkin kindreds (Families 1 through 8; see table 1) . Seven were first-degree relatives of isolated cases, and six were first-degree relatives of familial cases (two or more clinically affected) of an index patient with parkin disease.
All subjects underwent neurologic examination paying particular attention to the possible presence of mild extrapyramidal signs. All gave informed consent, and the Ethics Committees of the National Hospital for Neurology and Neurosurgery and the Hammersmith Hospitals Trust, London, UK approved the project. Permission to administer radiation was licensed by the Administration of Radioactive Substances Advisory Committee, UK.
Sixteen unrelated, age-and sex-matched control subjects (mean age, 54.6 Ϯ 13.9 years; range, 30 to 71 years) were scanned using the identical protocol as for the parkin heterozygotes. All normal control subjects reported no family history of parkinsonism and had a normal neurologic examination.
Molecular analysis. The coding regions of exons of the parkin gene were screened for mutations using reported methods. 4 Scanning protocol. 18 F-dopa PET scans were performed and analyzed using methods previously reported. 5 Two methods of analysis were used: a region of interest (ROI) approach, with ROIs placed on caudate and putamen nuclei, and statistical parametric mapping (SPM), allowing exploratory voxel-by-voxel comparisons between the parkin carrier group and the control group throughout the entire brain volume without requiring an a priori hypothesis. Detailed methods have been reported elsewhere. 5 ROI and SPM analysis was performed blinded to the status of the group of parkin heterozygotes and the group of control subjects.
Results. Clinical findings. Four heterozygotes had subtle extrapyramidal signs (see table 1 and video) that did not fulfill the UK Parkinson's Disease Society brain bank criteria for idiopathic PD (see table 1 ).
PET findings. Individual mean (left/right averaged) 18 F-dopa influx constant, Ki, values obtained with ROI analysis for 13 parkin heterozygotes and the mean of the control group are shown in table 2. As a group, mean parkin heterozygote caudate Ki values (0.0120 Ϯ 0.002) and mean putamen Ki values (0.0126 Ϯ 0.003) were reduced by 23% and 27% below the group means of control caudate Ki values (0.0153 Ϯ 0.003; p ϭ 0.0008) and putamen Ki values (0.0169 Ϯ 0.003; p ϭ 0.0022; see table 2).
These findings were confirmed by SPM analysis (figure). When compared with a group of healthy control subjects, asymptomatic parkin carriers showed bilateral decreases in 18 F-dopa uptake in the right and left putamen (x ϭ 22; y ϭ 13; z ϭ 3, Tailarach space; Z score ϭ 4.23; p Ͻ 0.0001; height threshold ϭ 0.001; and x ϭ Ϫ24; y ϭ 0; z ϭ 0, Tailarach space; Z score ϭ 4.87; p Ͻ 0.0001; height threshold ϭ 0.001) and right and left caudate (x ϭ 22; y ϭ 15; z ϭ 3, Tailarach space; Z score ϭ 3.23; p Ͻ 0.0001; height threshold ϭ 0.01; and x ϭ Ϫ15; y ϭ 14; z ϭ 7, Tailarach space; Z score ϭ 4.87; p Ͻ 0.0001; height threshold ϭ 0.01; see figure) .
Using this analysis, additional decreases in 18 threshold ϭ 0.001) and ventral midbrain (x ϭ 2; y ϭ Ϫ12; z ϭ Ϫ8, Tailarach space; Z score ϭ 3.14; p Ͻ 0.0001; height threshold ϭ 0.01) in heterozygote carriers compared with control subjects (see figure) .
Individually, eight parkin heterozygotes had a low normal putamen Ki Ͼ1.5 SDs below the normal mean, and six had a caudate Ki Ͼ1.5 SD below the normal mean; three subjects (2, 3, and 4) had caudate Ki values 2 SDs below normal mean; Subject 2, although without abnormal neurologic findings, had a mean putamen Ki value 2.5 SDs below the control mean (see table 2 ).
Discussion. This is the first in vivo study of dopamine terminal function in a large number of unrelated, asymptomatic parkin heterozygotes. We have shown a significant reduction in mean caudate, putamen, and midbrain 18 F-dopa uptake in these subjects with a similar uniform pattern to that reported in patients with clinical parkin disease. 2, 4, 6 Similar findings have also been reported in asymptomatic PARK6 heterozygotes. 3 Individual findings are of interest. Subject 13, although asymptomatic, had a postural tremor of both upper limbs at age 19 years. 6 Eleven years later, at age 30 years and still asymptomatic, 18 F-dopa PET showed severe nigrostriatal dopaminergic dysfunction with clinical signs that had progressed: mild resting tremor in both legs and reduced arm swing. 2 Three subjects (Subjects 2, 3, and 4) individually showed significant reductions in caudate dopamine storage compared with control subjects but had a normal examination. The disparity between the absence of clinical findings and significant nigrostriatal dopaminergic dysfunction compliments reports in parkin disease 2 and PARK6-linked parkinsonism, 3 suggesting that even if significant dopamine cell function loss occurs early, it may progress slowly enough to allow compensatory mechanisms to develop 7 in addition to increased pallidal dopamine stor- age that occurs in early PD. 8 These, in addition to altered production of nondopaminergic neurotransmitters, may operate to maintain motor status. We found no correlation between age of the heterozygote and the degree of dopamine terminal dysfunction. Subjects 2 and 4, with the lowest caudate influx constants, shared a point mutation in exon 12 at the C terminus of the protein, which may play an important role in cell growth and differentiation. Such base pair substitutions may have a greater "loss of function"; intact but inactive protein may interfere with parkin-mediated cellular pathways unlike deletions in which the protein is absent. Our findings suggest that either haploinsufficiency (single mutant allele reduces normal protein function by up to 50%) or a dominant negative effect (nonfunctional polypeptide physically interferes with the normal polypeptide) is sufficient to cause significant dopaminergic cell death and may be a risk factor for subclinical disease. Moreover, four subjects were "manifesting heterozygotes," implying that different parkin mutations impart different degrees of susceptibility to developing clinical signs. Repeated observation and PET scans will be necessary to confirm whether these cases go on to develop parkin disease.
Our findings may reflect changes associated with other undefined susceptibility alleles to PD rather than parkin or differences in the development of the dopaminergic system rather than subclinical decline: a study of postsynaptic D2-receptor binding and the functional status of dopaminergic transmission would seek to clarify the latter. The role of a parkin susceptibility allele in PD remains unclear, but cer-tain polymorphisms appear to be risk factors. 9 Moreover, a genomic screen of patients with idiopathic PD 10 has identified 17 patients with PD with mean age at onset of 49.2 years who were parkin heterozygotes, suggesting that parkin may be a susceptibility allele for late-onset PD. 
